Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management
Ryan Jay, Jaimie Rodger, Matthew Zirwas
Abstract
Dupilumab is a monoclonal antibody that treats atopic dermatitis by blocking interleukin (IL) 4 and IL-13 signaling.1 Dupilumab-associated inflammatory arthritis was first reported in 2019 in 3 patients who developed seronegative arthropathy and enthesitis within 16 weeks of starting the drug.2 Since then, only a few additional reports and 1 retrospective observational study have discussed this arthropathy in patients with atopic dermatitis. The pathophysiology, potential risk factors, clinical features, and response to therapy have not been well-characterized.
Topics & Concepts
DupilumabMedicineAtopic dermatitisDermatologyArthritisEnthesitisPsoriatic arthritisInflammatory arthritisImmunologyDermatology and Skin DiseasesUrticaria and Related ConditionsIL-33, ST2, and ILC Pathways